Specify Company / Ticker to Get the Summary
Brainstorm Cell Therapeutics Inc
BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Address: 1325 Avenue of Americas, New York, NY, United States, 10019
Analytics
WallStreet Target Price
23.45 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BCLI
Dividend Analytics BCLI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BCLI
Stock Valuation BCLI
Financials BCLI
Results | 2019 | Dynamics |